Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Predictive Oncology Announces Closing of $7.2 Million Registered Direct Offerings
EAGAN, Minn. , May 18, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has closed its
View HTML
Toggle Summary Predictive Oncology Announces $7.2 Million Registered Direct Offerings
EAGAN, Minn. , May 16, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into
View HTML
Toggle Summary Predictive Oncology Reports First Quarter Financial Results
EAGAN, Minn. , May 12, 2022 (GLOBE NEWSWIRE) -- The financial results from the first quarter we believe depicts a solid potential for growth in the upcoming period, in accordance with the report by Predictive Oncology Inc. (NASDAQ: POAI) today, disclosing the results for the quarter ended March 31,
View HTML
Toggle Summary Marketer with over 20 years of experience selected to head up marketing at Predictive Oncology
EAGAN, Minn. , April 26, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology  (NASDAQ: POAI) today announced that Theresa Ferguson has been named Senior Director of Marketing. As Predictive Oncology’s senior marketing leader, Ferguson steps in as the company begins commercialization of its
View HTML
Toggle Summary Predictive Oncology Reports Year End 2021 Financial Results and Provides Business Update
EAGAN, Minn. , March 31, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the year ended December 31, 2021 , a period defined
View HTML
Toggle Summary Predictive Oncology validates Discovery 21 proof-of-concept campaign
Predictive Oncology's Discovery 21 campaign evaluated the ability of its PeDAL® platform to make high-confidence predictions in ovarian tumor samples. Subsequent validation confirmed the accuracy and reproducibility of these predictions. MINNEAPOLIS , March 24, 2022 (GLOBE NEWSWIRE) -- Predictive
View HTML
Toggle Summary Predictive Oncology set to market AI drug discovery platform
MINNEAPOLIS , Jan. 27, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is set to be a first mover in the artificial intelligence (AI) powered drug discovery market that POAI expects will grow to $20 billion in the next three years, reported the Company today in outlining its
View HTML
Toggle Summary POAI Reports Strong Results From Its AI Cancer Drug Evaluation
MINNEAPOLIS , Jan. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) reported the preliminary results of its Discovery 2021 program today, announcing that its Helomics subsidiary’s evaluation demonstrated their proprietary Artificial Intelligence (AI) program CoRE™ (Computational
View HTML
Toggle Summary Predictive Oncology Adjourns Annual Meeting of Stockholders to December 30, 2021
MINNEAPOLIS , Dec. 27, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the Company’s Annual Meeting of Stockholders was convened at 3:00 p.m.
View HTML
Toggle Summary Predictive Oncology – Year-end Shareholder Update!
EAGAN, Minn. , Dec. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, is moving in the right direction. In November 2021 , POAI acquired zPREDICTA, a cutting edge cancer
View HTML